Brain Injury Association Logo

 

 WE'D LIKE TO THANK OUR SPONSORS:
 
 
 

FDA Approves Treatment for Pseudobulbar Affect

19-Nov-2010

Avanir Pharmaceuticals issued a press release about the FDA approval for Neudexta. Nuedexta is indicated for the treatment of pseudobulbar affect (PBA). PBA occurs secondary to a variety of otherwise unrelated neurological conditions, and is characterized by involuntary, sudden, and frequent episodes of laughing and/or crying. PBA episodes typically occur out of proportion or incongruent to the patient’s underlying emotional state.  Avanir distributed a press release about the medication and the approval.


 
© 2014 Brain Injury Association of America. All Rights Reserved. Website Maintained by: Chicago Digital

BRAIN INJURY ASSOCIATION OF AMERICA
1608 Spring Hill Road, Suite 110 • Vienna, VA 22182 • Phone: 703-761-0750 • Fax: 703-761-0755
National Brain Injury Information Center (Brain Injury Information Only) 1-800-444-6443

Fact Sheets  •  Legal Notices  •  Advertise  •  CONTACT US